10-hydroxydecenoic acid glycosylated derivative as well as preparation method and application thereof
By synthesizing 10-hydroxydecenoic acid and glycosylation, the good soluble antidepressant drugs in water are solved, and the existing antidepressant drugs have slow onset and many side effects are achieved, and the rapid and efficient antidepressant effects are achieved and safe Higher, similar to ketamine effects but avoids its addiction risk.
Patent Information
- Application Number
- CN202411092264.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
AI Technical Summary
Existing antidepressants have slow onset, low efficiency, recurrence and many side effects, and lack fast, efficient and safe treatment options. Especially for patients with moderate and severe depression, there is less confidence and hope for treatment. Existing drugs such as Ais Ketamine has an addiction risk and is difficult to use widely.
Develop 10-hydroxydecenoic acid glycosylated derivatives and preparation methods, and produce good soluble compounds in water by glycosylation of 10-hydroxydecenoic acid, which is used to prepare oral liquids or injections to improve the efficacy of antidepressants, and Improve the solubility and stability of the drug by adding solubilizers.
The prepared glycosylated derivatives have high solubility in water, and their antidepressant effects are significantly better than those of the prototype components. They can quickly relieve depression symptoms, have the effect close to ketamine and are significantly better than fluoxetine, providing a fast and safe antidepressant drug solution.
Smart Images

Figure CN118994274A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, and specifically relates to 10-hydroxydecenoic acid glycosidated derivatives and preparation methods and uses thereof. Background Art
[0002] The symptoms of depressive disorders are complex and varied, mainly manifested as significant and persistent emotions and low moods, which not only seriously affect work efficiency and quality of life, but are also accompanied by anhedonia, behavioral despair, sleep disorders, suicidal tendencies, etc. With the increasingly fierce social competition and the increasing pressure of study, work, social interaction and life, depression has become an extremely common mental illness in modern society. The number of depression patients among young and middle-aged people, pregnant women, and even college, middle school and elementary school students is showing a rising trend. According to estimates, there are more than 70 million depression patients in my country alone, including nearly 30 million patients under the age of 30. 30 million patients are the future and hope of 30 million families. Such a large number of patients not only cause great harm and mental pressure to individuals and families, but also bring a heavy burden to society.
[0003] For a long time, scientists at home and abroad have conducted a lot of research from multiple angles and at multiple levels, and found that depressive disorders have many causes and complex pathogenesis. Due to the complexity of the inducing factors and the great differences in the molecular mechanisms of pathological changes, there has been no decisive and breakthrough progress in the understanding of the core mechanisms and molecular targets of depression, which has affected the development of antidepressants. Clinically, there is a great lack of fast, efficient and safe antidepressants.
[0004] At present, the treatment of depression is mainly based on drug therapy, supplemented by psychological or physical stimulation therapy. However, the existing first-line antidepressant drugs, monoamine reuptake inhibitors, have the characteristics of slow onset (usually more than 2-3 weeks of medication to take effect), low efficacy (ineffective for about 1 / 3 of depressed patients), easy relapse (about half of patients relapse after treatment) and many side effects (common nausea, diarrhea, vomiting, sexual dysfunction, dizziness, restlessness, etc.). Since a considerable proportion of patients with moderate to severe depression have suicidal ideation, after these patients muster up the courage to seek medical treatment and medication, and after several weeks of drug treatment without any effect, and more obvious side effects or adverse reactions occur, depressed patients will feel that the hope of recovery is slim, strengthen the patient's helplessness / despair, and lose confidence in treatment. Therefore, the development of fast-acting antidepressants to shorten the onset time from about 2-4 weeks to several days, or even 2-3 days, is of extremely important clinical significance.
[0005] Due to the extreme lack of fast and highly effective antidepressants in clinical practice, in 2019, the United States and the European Union even took the risk of addiction / high toxic side effects and approved esketamine for the treatment of "refractory depression". Although the drug can quickly relieve depressive symptoms within a few hours, it is classified as a first-class psychotropic drug and is included in the category of drugs and is strictly controlled. When used as an antidepressant, there are risks of sedation, dissociation, and abuse addiction, making it difficult to be widely used clinically. Recently, the US FDA has newly approved the combination of dextromethorphan + bupropion to improve depression by inhibiting NMDA receptors, but dextromethorphan + bupropion is similar to ketamine and is still a psychoactive substance. It is urgent to find a fast, effective, safe and reliable antidepressant in clinical practice.
[0006] 10-Hydroxydecenoic acid (10-HDA), also known as royal jelly acid and 10-hydroxy-2-decenoic acid, is a natural unsaturated fatty acid with a unique structure that exists in royal jelly. 10-Hydroxydecenoic acid has multiple pharmacological activities such as antioxidant, immune enhancement, anti-inflammatory, antibacterial, anti-tumor, lipid-lowering and blood pressure-lowering. In addition, 10-Hydroxydecenoic acid has good safety and is an ideal lead compound for drug development from natural active molecules. However, there is currently no research and development of antidepressants based on 10-Hydroxydecenoic acid. Therefore, it is necessary to further develop 10-Hydroxydecenoic acid derivatives that have both ideal antidepressant activity and good safety. Summary of the invention
[0007] In view of the shortcomings of the prior art, the present invention provides a 10-hydroxydecenoic acid glycosylated derivative and a preparation method and use thereof. The technical scheme of the present invention is as follows: a compound represented by formula I or a pharmaceutically acceptable salt thereof or an isomer thereof
[0008]
[0009] R is selected from hydrogen or C1-C10 alkylcarbonyl.
[0010] Preferably, R is selected from hydrogen or methylcarbonyl.
[0011] The following compound or its pharmaceutically acceptable salt or isomer,
[0012]
[0013] The present invention also provides a method for preparing the compound of formula I, comprising the following steps:
[0014]
[0015] wherein R is selected from hydrogen or C1-C10 alkylcarbonyl, and X is selected from chlorine, bromine or iodine;
[0016] Dissolve 10-hydroxydecenoic acid and the compound of formula II in a solvent, add a catalyst under stirring, react under light protection, filter the reaction solution through diatomaceous earth, concentrate the filtrate and purify it through column chromatography to obtain the compound of formula I.
[0017] Preferably, the solvent is selected from dichloromethane, chloroform, carbon tetrachloride, dichloroethane, toluene, xylene or acetonitrile.
[0018] Preferably, the catalyst is selected from silver carbonate.
[0019] Preferably, the reaction time is 48 hours.
[0020] The present invention provides a composition comprising a compound of formula I, which comprises a therapeutically effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
[0021] Preferably, the composition comprises a compound of formula I and a solubilizer selected from Tween, polyethylene glycol, polysorbate, polyoxyethylene fatty acid ester, hydrogenated castor oil or meglumine.
[0022] The present invention provides use of the compound of formula I in preparing a drug for preventing and / or treating depression.
[0023] Beneficial effects of the present invention: The present invention designs and synthesizes a series of novel glycosylated derivatives of 10-hydroxydecenoic acid. The present invention unexpectedly found that: (1) the prepared glycosylated derivatives have good solubility in water, and their solubility in water is much higher than that of the prototype component 10-hydroxydecenoic acid. They can be directly dissolved in water to prepare oral liquid or injection, which is convenient for medication and has good antidepressant effect; (2) the recorded acetylated derivatives are difficult to dissolve in water, but their fat solubility is stronger than that of the prototype component 10-hydroxydecenoic acid, and their antidepressant efficacy is stronger than that of the original substance 10-hydroxydecenoic acid. Compared with the existing rapid antidepressant drug ketamine and the clinical first-line antidepressant fluoxetine, the glycosylated derivatives prepared by the present invention have significant effects on improving behavioral indicators, and their antidepressant effect is close to that of ketamine and significantly better than that of fluoxetine. Therefore, the compounds of the present invention provide ideas for the preparation of rapid antidepressant drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 : is the hydrogen spectrum of compound I-1
[0025] Figure 2 :Comparison of the antidepressant efficacy of 10-hydroxydecenoic acid and its glycosylated derivatives
[0026] A: 3 days after administration - social coefficient; B: 6 days after administration - social coefficient; C: 3 days after administration - swimming immobility time; D: 6 days after administration - swimming immobility time; Ac-X03: 10-hydroxydecenoic acid acetylated glycosylated derivative; X03: 10-hydroxydecenoic acid glycosylated derivative; 10-HAD: 10-hydroxydecenoic acid. *: ANOVA statistical analysis, p<0.05; **: ANOVA statistical analysis, p<0.01; ***: ANOVA statistical analysis, p<0.001.
[0027] Figure 3 :Antidepressant effects of two 10-hydroxydecenoic acid derivatives on the chronic social defeat depression model
[0028] A: 3 days after drug administration-social coefficient; B: 6 days after drug administration-social coefficient; C: 3 days after drug administration-swimming immobility time; D: 6 days after drug administration-swimming immobility time; E: 3 days after drug administration-tail suspension immobility time; F: 6 days after drug administration-tail suspension immobility time; I1: Ac-X03; I3: X03. *, #: ANOVA statistical analysis, p<0.05; **, ##: ANOVA statistical analysis, p<0.01; ***, ###: ANOVA statistical analysis, p<0.001; ns: ANOVA statistical analysis, p>0.05.
[0029] Figure 4 :Antidepressant effects of two 10-hydroxydecenoic acid derivatives on chronic unpredictable depression model
[0030] A: 3 days after administration-immobility time of swimming; B: 6 days after administration-immobility time of swimming; C: 3 days after administration-immobility time of tail suspension; D: 6 days after administration-immobility time of tail suspension; E: 6 days after administration-sugar preference coefficient. I1: Ac-X03; I3: X03.
[0031] *, #: ANOVA statistical analysis, p<0.05; **, ##: ANOVA statistical analysis, p<0.01; ***, ###: ANOVA statistical analysis, p<0.001; ns: ANOVA statistical analysis, p>0.05. DETAILED DESCRIPTION
[0032] The following embodiments can enable those skilled in the art to more fully understand the present invention, but the present invention is not limited to the scope of the embodiments.
[0033] Example 1 Synthesis of Compound Ac-X03 (I-1)
[0034]
[0035] 10-Hydroxydecenoic acid (1.86 g, 10 mmol) and bromoacetyl glucose (4.52 g, 11 mmol) were placed in a 100 mL reaction bottle, 20 mL of dichloromethane (DCM) was added, and silver carbonate (2.75 g, 10 mmol) was added under stirring. The reaction was allowed to react at room temperature for 48 hours under light protection. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated and purified by column chromatography. The developing solvent system was dichloromethane: methanol = 100:1 to 10:1. Finally, 2.06 g of colorless glassy semisolid was obtained with a yield of 40%. 1 H NMR(300MHz,Chloroform-d)δ7.12–6.94(m,1H),5.86–5.69(m,1H),5.35–4.89(m,3H),4.47(d,J=8.0Hz,1H),4.25(dd,J=12.3,4.6Hz,1H),4.12(dd,J =12.3,2.4Hz,1H),3.93–3.77(m,1H),3.78–3.58(m,1H),3.55–3.37(m,1H) ,2.28–2.15(m,2H),2.14–1.92(m,12H),1.64–1.25(m,10H).HRMS(ESI)for C 24 H 36 O 12 Na[M+Na] + calcd 539.2099, found 539.2082. The hydrogen spectrum of the compound is shown in Figure 1 .
[0036] Example 2 Synthesis of Compound Ac-X06 (I-2)
[0037]
[0038] The bromoacetyl glucose in the synthesis of Example 1 was replaced with bromoacetyl galactose. Finally, compound I-2 was obtained. HRMS (ESI) for C 24 H 36 O 12 Na[M+Na] + calcd 539.2099, found 539.2086.
[0039] Example 3 Synthesis of Compound X03 (I-3)
[0040]
[0041] Compound I-1 (516 mg, 1 mmol) was placed in a reaction flask, and ammonia methanol solution (7N, 2 mL) was added and stirred at room temperature for 24 hours. The organic matter and volatiles in the reaction solution were evaporated, and the residue was purified by column chromatography with a developing solvent system of isopropanol: water: acetic acid = 100:5:1. Finally, 54 mg of an amber syrupy compound was obtained with a yield of 15%. 1 H NMR(300MHz, Menthol-d4)δ7.11–6.96(m,1H),6.03–5.81(m,1H),5.67(d,J=8.0Hz,1H),3.35–4.01(m,6H),3.72(s,3H),3.35–3.11(m,2H),2.27 –2.11(m,2H),1.68(q,J=6.8Hz,2H),1.50(s,2H),1.44(d,J=7.2Hz,2H),1.38–1.29(m,4H),1.28–1.19(m,2H),0.92–0.79(m,2H).HRMS(ESI)forC 16 H 28 O 8 Na[M+Na] + calcd 371.1676, found 371.1678.
[0042] Example 4 Synthesis of Compound X06 (I-4)
[0043]
[0044] The compound I-1 in the synthesis of Example 3 was replaced by compound I-2. Finally, compound I-4 was obtained. HRMS (ESI) for C 16 H 28 O 8 Na[M+Na] + calcd 371.1676,found 371.1677.
[0045] Example 510 - Study on the Solution Formulation of Hydroxydecenoic Acid and Its Derivatives
[0046] Studies have found that 10-hydroxydecenoic acid has a good therapeutic effect on depression and Alzheimer's disease, but some patients have difficulty swallowing solid preparations, so they need to make oral solutions or injections for use. Because 10-hydroxydecenoic acid is difficult to dissolve in water, it is difficult to prepare it into oral solutions and injections by common means. Therefore, the study used methods such as changing the compound structure and adding solubilizers to conduct prescription research.
[0047] Based on a large number of preliminary studies and prescription screening, oral liquid and injection prescriptions were studied according to the prescriptions in Table 1. The basic steps are as follows: weigh 0.5g and 0.6g of meglumine respectively, dissolve in 8 ml of pure water, add 0.2g of 10-hydroxydecenoic acid and 10-hydroxydecenoic acid acetylated glycosylated derivative AC-X03 respectively, ultrasonicate for 2 minutes, oscillate to promote dissolution, add water to 10 ml, and shake to mix. In addition, with the above method, without adding meglumine, 10-hydroxydecenoic acid glycosylated derivative X03 is directly added to water to dissolve, ultrasonicate for 2 minutes, oscillate to promote dissolution, add water to 10 ml, and shake to mix. The above three solutions are packaged in EP tubes, 2 ml each, and placed at room temperature and 4°C for 24 hours, respectively, and the state of the solution is observed.
[0048] It was found that prescriptions 1 and 2 could be prepared into clear solutions, which remained unchanged whether refrigerated or placed at room temperature for 24 hours. In addition, even without adding the solubilizer meglumine, the solution of prescription 2 was clear and stable, which had obvious prescription advantages. However, the solution prepared by prescription 3 was turbid, and white precipitate appeared when refrigerated or placed at room temperature for 24 hours (Table 1).
[0049] Table 1 Study on the solution formulation of 10-hydroxydecenoic acid and its derivatives
[0050]
[0051] To investigate the solubility of 10-hydroxydecenoic acid and its derivatives in water, 5 conical flasks were taken and 10-hydroxydecenoic acid (10-HDA) (5 mg), Ac-X03 (10 mg), Ac-X06 (10 mg), X03 (200 mg) and X06 (200 mg) were added respectively. 10 mL of pure water was added to each conical flask, and the flask was sealed with a rubber stopper and placed on a magnetic stirrer and stirred thoroughly at 25 ° C. After stirring for 24 hours, the supernatant was centrifuged (2 mL, 2000 g, 5 minutes) and filtered using a filter head. According to the analytical method in the prior art CN 117338613A and J.Sep.Sci.2007,30,1061, the solubility of each compound in 25 ° C water (mg / mL water) was determined, as shown in Table 2.
[0052] Table 2 Results of solubility determination of 10-hydroxydecenoic acid and its derivatives in water
[0053]
[0054] Example 610-Hydroxydecenoic acid and its derivatives oral solution and preparation
[0055] Based on the prescription research results of Example 5, oral solutions of 10-hydroxydecenoic acid and its derivatives were prepared using purified water as a dispersion solvent, with concentrations of 10 and 30 mg / mL, respectively.
[0056] Table 3 Prescription and process of oral solution of 10-hydroxydecenoic acid and its derivatives
[0057]
[0058]
[0059] Preparation process: weigh 2.0 or 4.0 g of meglumine, dissolve in 80 ml of pure water, add 1.0 or 2.0 g of 10-hydroxydecenoic acid, ultrasonicate for 2 minutes, shake to dissolve, add water to 100 ml, shake and mix. Same as the above method, without adding meglumine, add 10-hydroxydecenoic acid glycosylated derivative X03 directly into water to dissolve, ultrasonicate for 2 minutes, shake to dissolve, add water to 100 ml, shake and mix. Filter through a 0.8 micron microporous membrane, package, the unit preparation is 10 mL, sterilize at 100 degrees circulating steam for 15 minutes, each containing 100 mg or 200 mg of 10-hydroxydecenoic acid or 10-hydroxydecenoic acid glycosylated derivative X03.
[0060] Example 710-Hydroxydecenoic acid and its derivatives injection and preparation
[0061] Based on the prescription research results of Example 5, injections of 10-hydroxydecenoic acid and its derivatives were prepared mainly with purified water as the dispersion solvent, with concentrations of 10 and 20 mg / mL, respectively, each containing 50 mg or 100 mg.
[0062] Table 4 Prescription and process of 10-hydroxydecenoic acid and its derivatives injection
[0063]
[0064] Preparation process: weigh 2.0 or 4.0 g of meglumine, dissolve in 80 ml of pure water, add 1.0 or 2.0 g of 10-hydroxydecenoic acid, ultrasonicate for 2 minutes, shake to dissolve, add 0.2 g of sodium chloride, add water to 100 ml, shake and mix. Same as the above method, without adding meglumine, add 10-hydroxydecenoic acid glycosylated derivative X03 directly into water to dissolve, ultrasonicate for 2 minutes, shake to dissolve, add 0.4 g of sodium chloride, add water to 100 ml, shake and mix. Add 0.1% activated carbon to the above solution, keep boiling for 5 minutes, filter with 0.8 micron microporous membrane, and package. The unit preparation is 5 mL, sterilize with 115 degrees circulating steam for 30 minutes, and each contains 50 mg or 100 mg of 10-hydroxydecenoic acid or 10-hydroxydecenoic acid glycosylated derivative X03.
[0065] Test Example 11 Comparison of the antidepressant efficacy of 0-hydroxydecenoic acid and its glycosylated derivatives on social defeat stress model mice
[0066] The social defeat stress model (CSDS) mice were used to evaluate the antidepressant efficacy. CD-1 mice (retired mice, male, 4-6 months, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., weight 48±5g) and C57BL / 6J mice (male, 7-8 weeks, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., weight 21±3g) were purchased and adaptively raised for one week under a standard breeding environment (free diet and drinking water, alternating day and night, 12 hours each).
[0067] Establishment of animal model: CD-1 mice were screened for 3 consecutive days, and aggressive CD-1 mice were selected for modeling. CD-1 mice and C57 mice were separated by a transparent plastic partition with holes. C57 mice were placed on the same side of CD-1 mice every day to accept the attack for 5-10 minutes each time. They were attacked by a new CD-1 mouse every day. After the attack, C57 mice were placed next to each other and continued to accept visual and taste stress from CD-1 mice for the remaining 24 hours. Modeling was continued for 10 days. On the 11th day, mice with a social coefficient <1 (i.e., depression-sensitive mice) were screened according to social avoidance behavior and were evenly divided into model group, 10-hydroxydecenoic acid acetylated derivative I1 (AcX03), 10-hydroxydecenoic acid glycosidated derivative I3 (X03), and 10-hydroxydecenoic acid for testing.
[0068] Administration method: Depression-sensitive mice were given 10-hydroxydecenoic acid (100 mg / kg, dispersed in 0.5% CMC-Na solution), 10-hydroxydecenoic acid acetylated glycosidic derivative AC-X03 (I1, 200 mg / kg, dispersed in 0.5% CMC-Na solution), and 10-hydroxydecenoic acid glycosidic derivative X03 (I3, 150 mg / kg, directly dissolved in water) by gavage, and the control group and model group were given an equal volume of 0.5% CMC-Na.
[0069] Social avoidance test (SI): The effect on the social avoidance behavior of mice was evaluated, and social behavior was evaluated after continuous administration for 3 and 6 days. Before the experiment, the mice were placed in the behavioral test room to adapt to the light and temperature for more than 30 minutes. C57 mice were placed in an open field of 40×40×40cm, and an empty mesh cage was placed in the social area. The activities of C57 mice were recorded within 150s, and the C57 mice were removed after the end. A CD-1 mouse was placed in the mesh cage for the second period of time, and the same 150s were recorded. The social coefficient (SI) was calculated as the ratio of the time that the C57 mouse entered the social area in the second period to the time that it entered the social area in the first period of time. The results showed that the social coefficient of the model group mice was significantly decreased compared with the control group. X03 oral solution administration for 3 days had a certain improvement on social avoidance behavior, but no significant difference was found. There was a significant change after 6 days of administration, which was close to the prototype drug. Ac-X03 oral administration for 3 and 6 days can significantly improve the social coefficient, and the effect is stronger than the prototype drug 10-HDA ( Figure 2 A, 2B).
[0070] Forced swimming test (FST): The forced swimming test (FST) was used to evaluate the desperation behavior of mice. C57 mice were placed in a 5-liter (11.8 cm in diameter, 27.5 cm in height) glass beaker (water level 18-20 cm, water temperature 23-25°C). The mice were visually isolated from each other, and the activity of the mice was recorded for 6 minutes. The time the mice remained motionless in the water within 4 minutes was analyzed by two blinded personnel. Activity was defined as swimming and climbing, and stillness was defined as floating or paddling slightly to keep the head out of the water. The results showed that the swimming immobility time of mice in the model group was significantly increased compared with that in the control group, and X03 administered as an oral solution for 3 and 6 days significantly reduced the swimming immobility time ( Figure 2 C, 2D), similar to the prototype drug; Ac-X03 administered intragastrically for 3 and 6 days significantly reduced the swimming immobility time, and the effect was stronger than that of the prototype drug 10-HDA ( Figure 2 C, 2D).
[0071] in conclusion : X03, an acetylated glycosylated derivative of 10-hydroxydecenoic acid, administered in the form of oral solution, has a more obvious improvement effect on the depressive-like behavior of CSDS model mice, and its efficacy is close to that of the prototype ingredient 10-hydroxydecenoic acid, suggesting that the improvement of water solubility does not affect the antidepressant efficacy after the glycosylation structure changes. Ac-X03, an acetylated glycosylated derivative of 10-hydroxydecenoic acid, administered in the form of suspension solution, can also significantly improve the depressive-like behavior of CSDS model mice, and its efficacy is better than that of the prototype ingredient 10-hydroxydecenoic acid, suggesting that it has structural advantages.
[0072] Test Example 2 Evaluation of the rapid antidepressant efficacy of 10-hydroxydecenoic acid glycosylated derivatives on social defeat stress model mice
[0073] The social defeat stress model (CSDS) mice were used to evaluate the antidepressant efficacy. CD-1 mice (retired mice, male, 4-6 months, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., weight 48±5g) and C57BL / 6J mice (male, 7-8 weeks, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., weight 21±3g) were purchased and adaptively raised for one week under a standard breeding environment (free diet and drinking water, alternating day and night, 12 hours each).
[0074] Establishment of animal model: CD-1 mice were screened for 3 consecutive days, and aggressive CD-1 mice were selected for modeling. CD-1 mice and C57 mice were separated by a transparent plastic partition with holes. C57 mice were placed on the same side of CD-1 mice every day to accept the attack for 5-10 minutes each time. They were attacked by a new CD-1 mouse every day. After the attack, C57 mice were placed next to each other and continued to accept visual and taste stress from CD-1 mice for the remaining 24 hours. Modeling was continued for 10 days. On the 11th day, mice with a social coefficient <1 (i.e., depression-sensitive mice) were screened according to social avoidance behavior and were evenly divided into the model group, 10-hydroxydecenoic acid acetylated derivative I1 (AcX03), 10-hydroxydecenoic acid glycosidated derivative I3 (X03), and ketamine group for experiment.
[0075] Administration method: Depression-sensitive mice were given 10-hydroxydecenoic acid acetylated derivative AC-X03 (I1, 200 mg / kg, dispersed in 0.5% CMC-Na solution) and 10-hydroxydecenoic acid glycosidated derivative X03 (I3, 150 mg / kg, directly dissolved in water) by gavage, and ketamine (10 mg / kg) was given by intraperitoneal injection. The control group and model group were given an equal volume of 0.5% CMC-Na.
[0076] Social avoidance test (SI): The effect on the social avoidance behavior of mice was evaluated, and social behavior was evaluated after 3 and 6 consecutive days of administration. Before the experiment, the mice were placed in the behavioral test room to adapt to the light and temperature for more than 30 minutes. C57 mice were placed in an open field of 40×40×40cm, and an empty mesh cage was placed in the social area. The activity of the C57 mice was recorded within 150s, and the C57 mice were removed after the end. A CD-1 mouse was placed in the mesh cage during the second period of time, and the recording was also performed for 150s. The social coefficient (SI) is calculated as the ratio of the time that the C57 mouse entered the social area during the second period to the time that it entered the social area during the first period. The results showed that the social coefficient of the model group mice was significantly decreased compared with that of the control group, and oral administration of Ac-X03 for 3 and 6 days could significantly increase the social coefficient ( Figure 3 A, 3B), X03 administration for 3 days and 6 days showed a certain improvement trend on social avoidance behavior, but no significant difference was found.
[0077] Forced swimming test (FST): The forced swimming test (FST) was used to evaluate the desperation behavior of mice. C57 mice were placed in a 5-liter (11.8 cm in diameter, 27.5 cm in height) glass beaker (water level 18-20 cm, water temperature 23-25°C). The mice were visually isolated from each other, and the activity of the mice was recorded for 6 minutes. The time the mice remained motionless in the water within 4 minutes was analyzed by two blinded personnel, where activity was defined as swimming and climbing, and stillness was defined as floating or paddling slightly to keep the head out of the water. The results showed that the swimming immobility time of mice in the model group was significantly increased compared with that in the control group, and oral administration of Ac-X03 for 3 and 6 days significantly reduced the swimming immobility time ( Figure 3 C, 3D), while X03 administration for 3 days significantly reduced the immobility time, and administration for 6 days could reduce the immobility time, but no significant statistical difference was observed ( Figure 3 C, 3D).
[0078] Tail suspension test (TST): The tail suspension test induces despair behavior in mice by suspending their tails, and records the immobility time of mice to evaluate their depression level. Wrap the tip of the tail of C57BL / 6J mice with medical white tape at 1 / 3, suspend them in a tail suspension box, use a camera to record their behavior within 6 minutes after suspension, and analyze the immobility time after 4 minutes. The results showed that the immobility time of the tail suspension of mice in the model group was significantly increased compared with that in the control group, and oral administration of Ac-X03 for 3 days did not significantly reduce the immobility time of the tail suspension ( Figure 3 E), but the 6-day administration significantly reduced the tail suspension immobility time ( Figure 3 F), while X03 administration had a significant effect on the tail suspension immobility time ( Figure 3 E, 3F).
[0079] in conclusion : X03, an acetylated glycosylated derivative of 10-hydroxydecenoic acid, administered in the form of oral solution, has a more obvious improvement effect on the depressive-like behavior of CSDS model mice. Ac-X03, an acetylated glycosylated derivative of 10-hydroxydecenoic acid, administered in the form of suspension solution, can also significantly improve the depressive-like behavior of CSDS model mice, and its efficacy is close to that of ketamine, indicating that it has a rapid and efficient antidepressant effect.
[0080] Test Example 3 Evaluation of the antidepressant efficacy of 10-hydroxydecenoic acid glycosylated derivatives on chronic unpredictable stress model mice
[0081] Establishment of chronic unpredictable stress animal model (CUMS): C57 mice were selected and adapted to 1% sucrose water. The sugar water preference coefficient was measured for 2 consecutive weeks as the baseline value. After the second week, the mice were randomly divided into groups according to the sugar water preference coefficient. Two of the following stresses were randomly given every day: ice water swimming (10 minutes), restraint (4 hours), wet bedding (12 hours), water and food deprivation (24 hours), social frustration (10 minutes), tail suspension (30 minutes), night light (12 hours), for 4 consecutive weeks.
[0082] Administration: The mice were given 10-hydroxydecenoic acid glycosylated derivative Ac-X03 (I1200 mg / kg, dispersed in 0.5% CMC-Na solution) and 10-hydroxydecenoic acid glycosylated derivative X03 (I3, 150 mg / kg, directly dissolved in water to prepare oral solution) by oral gavage for 6 consecutive days, and ketamine (10 mg / kg) and fluoxetine (20 mg / kg) were given by intraperitoneal injection. The control group and the model group were given an equal volume of 0.5% CMC-Na.
[0083] Sugar water preference test (SPT) detection: In order to examine the loss of interest behavior of mice, 1% sucrose water or drinking water was given, and the mice were pre-adapted for 24 hours before the experiment. The positions of the sugar water and drinking water bottles were swapped every 12 hours. During the experiment, the weight of the sugar water and drinking water consumed by the mice within 12 hours at night was weighed and recorded. The formula for calculating the sugar water preference coefficient is: drinking sugar water weight / (drinking sugar water weight + drinking pure water weight)*100%. The results showed that the sugar water preference score of the model mice was significantly decreased compared with the control group. The positive control ketamine significantly increased SPT, but the positive control fluoxetine failed to significantly increase SPT. Ac-X03 gavage for 6 days can significantly improve the social coefficient ( Figure 4 E), X03 administration for 6 days had some improvement on SPT, but no significant difference was found.
[0084] Forced swimming test (FST): The forced swimming test (FST) was used to evaluate the despair behavior of mice. C57 mice were placed in a 5-liter (11.8 cm in diameter, 27.5 cm in height) glass beaker (water level 18-20 cm, water temperature 23-25°C). The mice were visually isolated from each other, and the activity of the mice was recorded for 6 minutes. The time the mice remained motionless in the water within 4 minutes was analyzed by two blinded personnel, where activity was defined as swimming and climbing, and stillness was defined as floating or paddling slightly to keep the head out of the water. The results showed that the swimming immobility time of mice in the model group was significantly increased compared with that in the control group, ketamine could significantly improve the despair behavior of swimming immobility time, and oral administration of Ac-X03 for 3 and 6 days significantly reduced the swimming immobility time ( Figure 4 A, 4B), while X03 administration for 3 days significantly reduced the immobility time, and administration for 6 days could reduce the immobility time, but no significant statistical difference was observed ( Figure 4 A, 4B). The positive drug fluoxetine had no significant effect on FST after 6 days of administration.
[0085] Tail suspension test (TST): The tail suspension test induces despair behavior in mice by suspending their tails, and records the immobility time of mice to evaluate their depression levels. Wrap the tip of the tail of C57BL / 6J mice with medical white tape at 1 / 3, suspend them in a tail suspension box, use a camera to record their behavior within 6 minutes after suspension, and analyze the immobility time after 4 minutes. The results showed that the immobility time of the tail suspension of mice in the model group was significantly increased compared with that in the control group, ketamine can significantly improve the despair behavior of the tail suspension time, and oral administration of Ac-X03 for 3 days and 6 days significantly reduces the immobility time of the tail suspension ( Figure 4 C, 4D), X03 administration also had a significant effect on the tail suspension immobility time ( Figure 4 C, 4D). Fluoxetine, a positive drug, can reduce FST after 6 days of administration, but the difference is not significant.
[0086] in conclusion : X03, a glycosylated derivative of 10-hydroxydecenoic acid, administered in the form of oral solution, has a more obvious improvement effect on the depressive-like behavior of CUMS model mice, which is significantly better than fluoxetine. Ac-X03, an acetylated derivative of 10-hydroxydecenoic acid, administered in the form of suspension solution, can significantly improve the depressive-like behavior of CUMS model mice, and its efficacy is close to ketamine, which is significantly better than fluoxetine, indicating that it has a rapid and efficient antidepressant effect.
Claims
1. A compound of formula I or a pharmaceutically acceptable salt or an isomer thereof Wherein R is selected from hydrogen or C1-C10 alkylcarbonyl.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or an isomer thereof, characterized in that: R is selected from hydrogen or methylcarbonyl.
3. The following compounds or their pharmaceutically acceptable salts or isomers, 4. The method for preparing the compound of formula I according to claim 1, comprising the following steps: wherein R is selected from hydrogen or C1-C10 alkylcarbonyl, and X is selected from chlorine, bromine or iodine; Dissolve 10-hydroxydecenoic acid and the compound of formula II in a solvent, add a catalyst under stirring, react under light protection, filter the reaction solution through diatomaceous earth, concentrate the filtrate and purify it through column chromatography to obtain the compound of formula I.
5. The preparation method according to claim 4, characterized in that: The solvent is selected from dichloromethane, chloroform, carbon tetrachloride, ethylene dichloride, toluene, xylene or acetonitrile.
6. The preparation method according to claim 4, characterized in that: The catalyst is selected from silver carbonate.
7. The preparation method according to claim 4, characterized in that: The reaction time is 48h.
8. A composition comprising a compound of formula I, comprising a therapeutically effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
9. The composition according to claim 8, characterized in that The composition comprises a compound of formula I and a solubilizer, wherein the solubilizer is selected from Tween, polyethylene glycol, polysorbate, polyoxyethylene fatty acid ester, hydrogenated castor oil or meglumine.
10. Use of the compound of formula I according to claim 1 in the preparation of a medicament for preventing and / or treating depression.
